Presence and the roles of IL-9/Th9 axis in vitiligo.
IFNγ
IL-9
Th9 cells
melanocytes
vitiligo
Journal
Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
16
03
2021
received:
22
10
2020
accepted:
04
04
2021
pubmed:
10
4
2021
medline:
5
2
2022
entrez:
9
4
2021
Statut:
ppublish
Résumé
Immune dysregulation is critical in vitiligo pathogenesis. Although the presence and roles of numerous CD4
Substances chimiques
IL9 protein, human
0
IL9R protein, human
0
Interleukin-9
0
Receptors, Interleukin-9
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
966-972Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Bach, E. A., Aguet, M., & Schreiber, R. D. (1997). The IFN gamma receptor: A paradigm for cytokine receptor signaling. Annual Review of Immunology, 15, 563-591. https://doi.org/10.1146/annurev.immunol.15.1.563
Bassiouny, D. A., & Shaker, O. (2011). Role of interleukin-17 in the pathogenesis of vitiligo. Clinical and Experimental Dermatology, 36(3), 292-297. https://doi.org/10.1111/j.1365-2230.2010.03972.x
Czarnowicki, T., He, H., Leonard, A., Kim, H. J., Kameyama, N., Pavel, A. B., Li, R., Estrada, Y., Wen, H., Kimmel, G. W., Kim, H. J., Chima, M., Lebwohl, M., Krueger, J. G., & Guttman-Yassky, E. (2019). Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. Journal of Allergy and Clinical Immunology, 143(6), 2095-2107. https://doi.org/10.1016/j.jaci.2018.11.031
Das, S., Srinivasan, S., Srivastava, A., Kumar, S., Das, G., Das, S., Dwivedi, A., Karulkar, A., Makkad, K., Bilala, R., Gupta, A., Sawant, A., Nayak, C., Tayalia, P., & Purwar, R. (2019). Differential influence of IL-9 and IL-17 on actin cytoskeleton regulates the migration potential of human keratinocytes. The Journal of Immunology, 202(7), 1949-1961. https://doi.org/10.4049/jimmunol.1800823
Dwivedi, A., Kumar, S., & Purwar, R. (2017). B16 lung melanoma model to study the role of Th9 cells in cancer. Methods in Molecular Biology, 1585, 217-222. https://doi.org/10.1007/978-1-4939-6877-0_17
Ezzedine, K., Eleftheriadou, V., Whitton, M., & van Geel, N. (2015). Vitiligo. The Lancet, 386(9988), 74-84. https://doi.org/10.1016/S0140-6736(14)60763-7
Gittler, J. K., Shemer, A., Suarez-Farinas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., & Guttman-Yassky, E. (2012). Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. Journal of Allergy and Clinical Immunology, 130(6), 1344-1354. https://doi.org/10.1016/j.jaci.2012.07.012
Harris, J. E., Harris, T. H., Weninger, W., Wherry, E. J., Hunter, C. A., & Turka, L. A. (2012). A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. The Journal of Investigative Dermatology, 132(7), 1869-1876. https://doi.org/10.1038/jid.2011.463
Katz, K. L., Rupley, K., Sink, J., Shuley, A., & Gottlieb, A. B. (2018). Interleukin-17 inhibition in a patient with psoriasis and concurrent vitiligo. Journal of Psoriasis and Psoriatic Arthritis, 3(4), 126-130. https://doi.org/10.1177/2475530318788943
Kotobuki, Y., Tanemura, A., Yang, L., Itoi, S., Wataya-Kaneda, M., Murota, H., Fujimoto, M., Serada, S., Naka, T., & Katayama, I. (2012). Dysregulation of melanocyte function by Th17-related cytokines: Significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell & Melanoma Research, 25(2), 219-230. https://doi.org/10.1111/j.1755-148X.2011.00945.x
Kumar, S., Dhamija, B., Marathe, S., Ghosh, S., Dwivedi, A., Karulkar, A., Sharma, N., Sengar, M., Sridhar, E., Bonda, A., Thorat, J., Tembhare, P., Shet, T., Gujral, S., Bagal, B., Laskar, S., Jain, H., & Purwar, R. (2020). The Th9 axis reduces the oxidative stress and promotes the survival of malignant T Cells in cutaneous T-cell lymphoma patients. Molecular Cancer Research, 18(4), 657-668. https://doi.org/10.1158/1541-7786.MCR-19-0894
Kupper, T. S., & Purwar, R. (2017). Use of Th9 cells and IL-9 for the treatment of melanoma: Google patents.
Kurien, B. T., & Scofield, R. H. (2008). Autoimmunity and oxidatively modified autoantigens. Autoimmunity Reviews, 7(7), 567-573. https://doi.org/10.1016/j.autrev.2008.04.019
Le Poole, I. C., & Mehrotra, S. (2017). Replenishing regulatory T cells to halt depigmentation in vitiligo. The Journal of Investigative Dermatology. Symposium Proceedings, 18(2), S38-S45. https://doi.org/10.1016/j.jisp.2016.10.023
Ma, L., Xue, H. B., Guan, X. H., Shu, C. M., Zhang, J. H., & Yu, J. (2014). Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clinical & Experimental Immunology, 175(1), 25-31. https://doi.org/10.1111/cei.12198
Marathe, S., Dhamija, B., Kumar, S., Jain, N., Ghosh, S., Dharikar, J. P., Srinivasan, S., Das, S., Sawant, A., Desai, S., Khan, F., Syiemlieh, A., Munde, M., Nayak, C., Gandhi, M., Kumar, A., Srivastava, S., Venkatesh, K., Barthel, S. R., & Purwar, R. (2021). Multi-omics analysis and systems biology integration identifies the roles of IL-9 in keratinocyte metabolic reprogramming. Journal of Investigative Dermatology. S0022-202X(21)00237-2. https://doi.org/10.1016/j.jid.2021.02.013
Natarajan, V. T., Ganju, P., Singh, A., Vijayan, V., Kirty, K., Yadav, S., Puntambekar, S., Bajaj, S., Dani, P. P., Kar, H. K., Gadgil, C. J., Natarajan, K., Rani, R., & Gokhale, R. S. (2014). IFN-gamma signaling maintains skin pigmentation homeostasis through regulation of melanosome maturation. Proceedings of the National Academy of Sciences USA, 111(6), 2301-2306. https://doi.org/10.1073/pnas.1304988111
Niehues, H., Smits, J. P. H., Rodijk-Olthuis, D., Schalkwijk, J., & van den Bogaard, E. H. (2017). Keratinocyte proliferation and differentiation on IL-9 stimulation: An explorative in vitro study. Acta Dermato Venereologica, 97(6), 741-742. https://doi.org/10.2340/00015555-2643
Ouyang, H., Shi, Y., Liu, Z., Feng, S., Li, L., Su, N., Lu, Y., & Kong, S. (2013). Increased interleukin9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Molecular Medicine Reports, 7(3), 1031-1037. https://doi.org/10.3892/mmr.2013.1258
Purwar, R., Werfel, T., & Wittmann, M. (2006). IL-13-stimulated human keratinocytes preferentially attract CD4+CCR4+ T cells: Possible role in atopic dermatitis. Journal of Investigative Dermatology, 126(5), 1043-1051. https://doi.org/10.1038/sj.jid.5700085
Purwar, R., Werfel, T., & Wittmann, M. (2007). Regulation of IL-13 receptors in human keratinocytes. Journal of Investigative Dermatology, 127(5), 1271-1274. https://doi.org/10.1038/sj.jid.5700687
Rashighi, M., Agarwal, P., Richmond, J. M., Harris, T. H., Dresser, K., Su, M. W., Zhou, Y., Deng, A., Hunter, C. A., Luster, A. D., & Harris, J. E. (2014). CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Science Translational Medicine, 6(223), 223ra223. https://doi.org/10.1126/scitranslmed.3007811
Schlapbach, C., Gehad, A., Yang, C., Watanabe, R., Guenova, E., Teague, J. E., Campbell, L., Yawalkar, N., Kupper, T. S., & Clark, R. A. (2014). Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Science Translational Medicine, 6(219), 219ra218. https://doi.org/10.1126/scitranslmed.3007828
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004). Interferon-gamma: An overview of signals, mechanisms and functions. Journal of Leukocyte Biology, 75(2), 163-189. https://doi.org/10.1189/jlb.0603252
Singh, T. P., Schon, M. P., Wallbrecht, K., Gruber-Wackernagel, A., Wang, X. J., & Wolf, P. (2013). Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One, 8(1), e51752. https://doi.org/10.1371/journal.pone.0051752
Speeckaert, R., Mylle, S., & van Geel, N. (2019). IL-17A is not a treatment target in progressive vitiligo. Pigment Cell & Melanoma Research, 32(6), 842-847. https://doi.org/10.1111/pcmr.12789
Speeckaert, R., Speeckaert, M. M., & van Geel, N. (2015). Why treatments do(n't) work in vitiligo: An autoinflammatory perspective. Autoimmunity Reviews, 14(4), 332-340. https://doi.org/10.1016/j.autrev.2014.12.003
Srinivasan, S., Ashok, V., Mohanty, S., Das, A., Das, S., Kumar, S., Sen, S., & Purwar, R. (2017). Blockade of Rho-associated protein kinase (ROCK) inhibits the contractility and invasion potential of cancer stem like cells. Oncotarget, 8(13), 21418-21428. https://doi.org/10.18632/oncotarget.15248
van den Boorn, J. G., Konijnenberg, D., Dellemijn, T. A., van der Veen, J. P., Bos, J. D., Melief, C. J., Vyth-Dreese, F. A., & Luiten, R. M. (2009). Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. Journal of Investigative Dermatology, 129(9), 2220-2232. https://doi.org/10.1038/jid.2009.32
Wang, S., Zhou, M., Lin, F., Liu, D., Hong, W., Lu, L., Zhu, Y., & Xu, A. (2014). Interferon-gamma induces senescence in normal human melanocytes. PLoS One, 9(3), e93232. https://doi.org/10.1371/journal.pone.0093232
Webb, K. C., Tung, R., Winterfield, L. S., Gottlieb, A. B., Eby, J. M., Henning, S. W., & Le Poole, I. C. (2015). Tumour necrosis factor-alpha inhibition can stabilize disease in progressive vitiligo. The British Journal of Dermatology, 173(3), 641-650. https://doi.org/10.1111/bjd.14016
Yanaba, K., Yoshizaki, A., Asano, Y., Kadono, T., & Sato, S. (2011). Serum interleukin 9 levels are increased in patients with systemic sclerosis: Association with lower frequency and severity of pulmonary fibrosis. Journal of Rheumatology, 38(10), 2193-2197. https://doi.org/10.3899/jrheum.110268
Yang, L., Wei, Y., Sun, Y., Shi, W., Yang, J., Zhu, L., & Li, M. (2015). Interferon-gamma Inhibits melanogenesis and Induces apoptosis in melanocytes: A pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo. Acta Dermato Venereologica, 95(6), 664-670. https://doi.org/10.2340/00015555-2080